CORSTASIS THERAP
PharmaCORSTASIS THERAP is a pharmaceutical company focused on Cardiovascular, Gastroenterology. Key products include ENBUMYST.
CORSTASIS THERAP's Key Drugs
CORSTASIS THERAP's core commercial portfolio centers on ENBUMYST, spanning Cardiovascular and Gastroenterology — its most strategically important drugs approved in the last 15 years.
CORSTASIS THERAP's Recent FDA Approvals
CORSTASIS THERAP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
CORSTASIS THERAP's Therapeutic Areas
CORSTASIS THERAP's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CORSTASIS THERAP's Top Competitors
CORSTASIS THERAP's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Takeda, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CORSTASIS THERAP Pipeline Snapshot
Active clinical trials for CORSTASIS THERAP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ENBUMYST leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-09-12
- Latest
- 2025-09-12
- Applications
- 1